| Title | Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer |
| Author | |
| Corresponding Author | Zhou, Xuhui |
| Publication Years | 2022-07-01
|
| DOI | |
| Source Title | |
| ISSN | 2366-004X
|
| EISSN | 2366-0058
|
| Abstract | ["Purpose To investigate the diagnostic value of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) for clinically significant prostate cancer (CsPCa). We also aimed to combine PI-RADS v2.1 with prostate-specific antigen (PSA) derivatives to improve the predictive value of CsPCa.","Methods We retrospectively collected relevant data who underwent standard MRI examinations of the prostate and subjected to a prostate biopsy at Shenzhen People's hospital from November 2014 to November 2019. Included 125 cases of CsPCa and 383 cases of non-CsPCa. All cases were scored using the PI-RADS v2.1. The clinical data collected included age, PSA, free PSA/total PSA, prostate volume and PSA density (PSAD). A univariate analysis was performed to identify statistically significant indicators. Logistic regression was used to analyze the predictive value of the multi-parameter combination on CsPCa.","Results Except age, the difference in all of indicators between the CsPCa group and non-CsPCa group was statistically significant. The PI-RADS score and PSAD value had the highest diagnostic value. Logistic regression analysis revealed that the PI-RADS score and PSAD value were independent predictors of CsPCa, with a regression model AUC of 0.935. CsPCa detection rates were low when the PI-RADS score <= 2 or the PI-RADS score = 3 and the PSAD value <= 0.33 ng/ml/ml.","Conclusion Combining the PI-RADS score and PSAD value improved the predictive performance of CsPCa. Patients with a PI-RADS score <= 2 or a PI-RADS score = 3 and a PSAD value <= 0.33 ng/ml/ml can avoid an unnecessary biopsy."] |
| Keywords | |
| URL | [Source Record] |
| Indexed By | |
| Language | English
|
| SUSTech Authorship | Others
|
| WOS Research Area | Radiology, Nuclear Medicine & Medical Imaging
|
| WOS Subject | Radiology, Nuclear Medicine & Medical Imaging
|
| WOS Accession No | WOS:000821973300002
|
| Publisher | |
| Data Source | Web of Science
|
| Citation statistics |
Cited Times [WOS]:2
|
| Document Type | Journal Article |
| Identifier | http://kc.sustech.edu.cn/handle/2SGJ60CL/355863 |
| Department | Shenzhen People's Hospital |
| Affiliation | 1.Sun Yat Sen Univ, Affiliated Hosp 8, Dept Radiol, 3025 Sherman Middle Rd, Shenzhen 518036, Peoples R China 2.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Radiol, Shenzhen 518020, Peoples R China 3.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen 518020, Peoples R China 4.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Pathol, Shenzhen 518020, Peoples R China |
| Recommended Citation GB/T 7714 |
Wei, Xiaoting,Xu, Jianmin,Zhong, Shuyuan,et al. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer[J]. Abdominal Radiology,2022.
|
| APA |
Wei, Xiaoting.,Xu, Jianmin.,Zhong, Shuyuan.,Zou, Jinsen.,Cheng, Zhiqiang.,...&Zhou, Xuhui.(2022).Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.Abdominal Radiology.
|
| MLA |
Wei, Xiaoting,et al."Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer".Abdominal Radiology (2022).
|
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment